```html

Polyp (Nasal) – A Complete Medical Guide

Overview

Nasal polyps are soft, painless, non‑cancerous growths that develop on the lining of the nasal passages or sinuses. They are typically teardrop‑shaped or grape‑like and arise from chronic inflammation of the nasal mucosa. While a single polyp can be asymptomatic, multiple polyps can block airflow, leading to a range of symptoms.

• Who it affects: Adults between 30–60 years old are most commonly diagnosed, but children can develop polyps, especially those with cystic fibrosis or allergic diseases.
• Prevalence: Epidemiologic studies estimate that 1–4 % of the general population have nasal polyps, with higher rates (up to 15 %) in patients with chronic rhinosinusitis.
• Gender differences: Women are slightly more likely than men to develop polyps (approximately 55 % vs. 45 %).
• Ethnicity: Higher prevalence reported in individuals of European descent; lower rates in Asian populations, suggesting a genetic component.

Symptoms

Symptoms vary with the size, number, and location of polyps. Some people remain unaware until an incidental finding on imaging, while others experience significant morbidity.

Upper‑airway symptoms

• Chronic nasal congestion – a feeling of a “blocked” nose that persists for months.
• Runny nose (rhinorrhea) – often clear or watery, sometimes with a thick mucus.
• Reduced sense of smell (hyposmia) or complete loss (anosmia) – one of the most common early signs.
• Post‑nasal drip – mucus drips down the back of the throat, causing throat clearing.
• Sneezing – typically less intense than classic allergic rhinitis.

Sinus‑related symptoms

• Facial pressure or pain – especially around the cheeks, forehead, or eyes.
• Headache – often worsens when bending forward.
• Ear fullness – due to Eustachian tube blockage, sometimes causing muffled hearing.

Other possible manifestations

• Sleep disturbance – snoring or obstructive sleep apnea in severe cases.
• Bad breath (halitosis) – from stagnant mucus.
• Voice changes – a nasal or “stuffed” quality.

Causes and Risk Factors

The exact cause is unknown, but nasal polyps are strongly linked to chronic inflammation of the sinus mucosa. The following factors increase the likelihood of developing polyps:

• Chronic rhinosinusitis (CRS) – persistent inflammation for >12 weeks; the most common precursor (up to 85 % of patients with polyps).
• Allergic rhinitis (hay fever) – especially in people with high IgE levels.
• Asthma – especially aspirin‑sensitive (Samter’s) triad: asthma, nasal polyps, and aspirin intolerance.
• Cystic fibrosis (CF) – up to 30 % of CF patients develop nasal polyps early in life.
• Non‑steroidal anti‑inflammatory drug (NSAID) sensitivity – up to 20 % with NSAID‑exacerbated respiratory disease (NERD) develop polyps.
• Environmental exposures – occupational irritants (dust, chemicals), tobacco smoke, and air pollution can aggravate sinus inflammation.
• Genetic predisposition – family studies suggest a heritable component; several cytokine gene polymorphisms (e.g., IL‑4, IL‑13) have been implicated.
• Immune dysregulation – abnormal eosinophil activity and altered epithelial barrier function.

Diagnosis

Diagnosing nasal polyps involves a combination of patient history, physical examination, and imaging when necessary.

Clinical evaluation

• History taking – duration of symptoms, allergy or asthma history, NSAID sensitivity, past sinus infections.
• Nasal endoscopy – a flexible or rigid scope inserted into the nostril provides direct visualization of polyps, mucosal edema, and secretions. This is the gold standard for diagnosis.

Imaging studies

• Computed Tomography (CT) scan of sinuses – offers detailed anatomy, helps grade disease severity (Lund‑Mackay scoring), and rules out other pathologies such as fungal sinusitis or tumors.
• Magnetic Resonance Imaging (MRI) – used in selected cases (e.g., suspicion of invasive fungal disease or neoplasm) because of superior soft‑tissue contrast.

Allergy and immune testing

• Skin prick testing or serum-specific IgE to identify allergic triggers.
• Blood eosinophil count – elevated levels often correlate with eosinophilic polyps.

Laboratory work‑up (optional)

• Complete blood count (CBC) – to assess eosinophilia.
• Total IgE – may be elevated in atopic individuals.

Treatment Options

Treatment aims to shrink polyps, alleviate symptoms, and prevent recurrence. A stepwise approach is commonly used: medical therapy first, followed by surgery if needed.

Medications

• Intranasal corticosteroid sprays (e.g., fluticasone, mometasone, budesonide) – first‑line; reduce polyp size in up to 50 % of patients after 8–12 weeks.<sup>1</sup>
• Oral corticosteroids – short courses (5–14 days) are effective for rapid polyp reduction, but long‑term use is limited by side‑effects.
• Biologic agents – monoclonal antibodies targeting type‑2 inflammation (e.g., dupilumab, omalizumab, mepolizumab). FDA‑approved dupilumab for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2020; shows a 68 % reduction in polyp size in pivotal trials.<sup>2</sup>
• Leukotriene modifiers (e.g., montelukast) – modest benefit, particularly in aspirin‑sensitive patients.
• Saline nasal irrigation – isotonic or hypertonic solutions help clear mucus and improve topical drug delivery.
• Antibiotics – only indicated for acute bacterial sinus infections; not routinely used for polyps alone.

Procedural interventions

• Endoscopic sinus surgery (ESS) – removal of polyps and opening of sinus ostia to restore ventilation. Indicated when:
  • Medical therapy fails after ≥3 months, or
  • Severe obstruction causing sleep apnea, chronic infections, or facial pain.
  Post‑operative care includes nasal steroids and regular irrigations to lower recurrence (≈40 % recurrence within 5 years without biologics).<sup>3</sup>
• Balloon sinuplasty – a less invasive dilation of sinus openings; suitable for limited disease.

Lifestyle and supportive measures

• Allergen avoidance (dust‑mite covers, air purifiers).
• Smoking cessation – tobacco smoke worsens sinus inflammation.
• Weight management – obesity is linked to higher eosinophilic activity.
• Daily nasal saline rinses (e.g., using a neti pot) – 1–2 times per day.

Living with Nasal Polyps

Even after treatment, many individuals experience intermittent symptoms. The following strategies promote long‑term control:

• Adherence to nasal sprays – use consistently, even when symptoms improve.
• Scheduled follow‑up – ENT visits every 3–6 months in the first year, then annually.
• Monitor sense of smell – a sudden loss may herald polyp growth.
• Manage comorbid conditions – optimal asthma control (e.g., inhaled steroids) reduces polyps recurrence.
• Stay hydrated – thin mucus secretions are easier to clear.
• Use a humidifier in dry climates to keep nasal mucosa moist.

Prevention

While not all polyps are preventable, risk can be reduced:

• Control allergic rhinitis with antihistamines and intranasal steroids.
• Avoid NSAIDs if you have aspirin‑exacerbated respiratory disease; discuss alternatives with your physician.
• Maintain good sinus hygiene: daily saline irrigation and regular cleaning of nasal filters.
• Address environmental irritants – use protective masks in dusty jobs.
• Vaccinate against influenza and COVID‑19 to lower the chance of secondary sinus infections.

Complications

If left untreated or poorly managed, nasal polyps may lead to:

• Chronic sinus infections – bacterial overgrowth behind obstructed sinuses.
• Osteitis – inflammation of the bone surrounding the sinuses.
• Obstructive sleep apnea – airway narrowing during sleep.
• Reduced quality of life – chronic fatigue, cognitive fog, and mood disturbances linked to smell loss.
• Rare malignancy – while polyps are benign, prolonged inflammation can rarely mask sinonasal tumors; hence, persistent unilateral symptoms warrant evaluation.

When to Seek Emergency Care

References

1. Mayo Clinic. Nasal Polyps: Diagnosis & Treatment. Updated 2023.
2. Roh JY, et al. Dupilumab for chronic rhinosinusitis with nasal polyps: Results from the Phase III LIBERTY trials. J Allergy Clin Immunol. 2021;148(3):662‑672.
3. European Position Paper on Rhinosinusitis and Nasal Polyps 2022 (EPOS2022). EPOS2022.org. Consensus recommendations on surgery and recurrence rates.

```